Overall medical encounters in patients with T2DM and TUD (without obesity) (Comparision between matched semaglutide vs other anti-diabetes medications cohorts)

Size/cohort	Exposure	Comparison	cases (overall risk) (Exposure)	cases (overall risk) (Comparison)	RD (95% CI)			HR (95% CI)
1,302	semaglutide	insulins	1,267 (97.3%)	1,201 (92.2%)	5.1% (3.4%, 6.8%)	 ■ 		0.81 (0.75–0.87)
1,305	semaglutide	metformin	1,269 (97.2%)	1,226 (93.9%)	3.3% (1.7%, 4.9%)	ŀ	 	1.05 (0.97–1.14)
1,283	semaglutide	DPP-4i	1,248 (97.3%)	1,213 (94.5%)	2.7% (1.2%, 4.3%)	F	∍ ⊣	1.03 (0.95–1.12)
1,293	semaglutide	SGLT2i	1,257 (97.3%)	1,229 (95.1%)	2.2% (0.7%, 3.6%)	H	H	0.99 (0.92–1.07)
1,292	semaglutide	SU	1,256 (97.2%)	1,210 (93.7%)	3.6% (2.0%, 5.2%)	1	=-	1.08 (0.99–1.17)
1,033	semaglutide	TZD	1,000 (96.8%)	957 (92.6%)	4.2% (2.2%, 6.1%)	ŀ	-	1.08 (0.98–1.18)
1,268	semaglutide	other GLP-1RAs	1,233 (97.2%)	1,187 (93.6%)	3.6% (2.0%, 5.2%)	ŀ	 	1.06 (0.98–1.15)
	0.30 0.40 0.60 0.801.0 2.0 3.00 Hazard Ratio (HR)							